Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Long-Term Investments (2019 - 2025)

Fate Therapeutics' Long-Term Investments history spans 7 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Long-Term Investments fell 94.68% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, down 94.68%, while the annual FY2025 figure was $1.5 million, 94.68% down from the prior year.
  • Long-Term Investments reached $1.5 million in Q4 2025 per FATE's latest filing, down from $10.3 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $149.5 million in Q2 2021 to a low of $980000.0 in Q4 2023.
  • Average Long-Term Investments over 5 years is $40.5 million, with a median of $26.1 million recorded in 2025.
  • Peak YoY movement for Long-Term Investments: tumbled 95.09% in 2022, then surged 2722.14% in 2024.
  • A 5-year view of Long-Term Investments shows it stood at $100.7 million in 2021, then crashed by 95.09% to $4.9 million in 2022, then crashed by 80.17% to $980000.0 in 2023, then soared by 2722.14% to $27.7 million in 2024, then tumbled by 94.68% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Long-Term Investments are $1.5 million (Q4 2025), $10.3 million (Q3 2025), and $26.1 million (Q2 2025).